FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Kelderman Kim
  2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Pres. Diagnostics & Genom
(Last)
(First)
(Middle)
614 MCKINLEY PLACE NE
3. Date of Earliest Transaction (Month/Day/Year)
09/22/2021
(Street)

MINNEAPOLIS, MN 55413
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/22/2021   S(1)   822 D $ 529.04 0 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $ 150.78               (2) 05/01/2025 Common Stock 2,652   2,652 D  
Stock Options (Right to Buy) $ 150.78               (3) 05/01/2025 Common Stock 7,348   7,348 D  
Stock Options (Right to Buy) $ 177.32               (4) 08/08/2025 Common Stock 12,044   12,044 D  
Stock Options (Right to Buy) $ 177.32               (5) 08/08/2025 Common Stock 9,033   9,033 D  
Restricted Stock Units (6)               (7)   (7) Common Stock 2,363   2,363 D  
Stock Options (Right to Buy) $ 190.41               (7) 08/07/2026 Common Stock 11,961   11,961 D  
Stock Options (Right to Buy) $ 190.41               (8) 08/07/2026 Common Stock 15,948   15,948 D  
Restricted Stock Units (6)               (9)   (9) Common Stock 2,015   2,015 D  
Stock Options (Right to Buy) $ 267.87               (9) 08/05/2027 Common Stock 8,991   8,991 D  
Stock Options (Right to Buy) $ 267.87               (10) 08/05/2027 Common Stock 11,988   11,988 D  
Stock Options (Right to Buy) $ 267.87               (11) 08/05/2027 Common Stock 8,325   8,325 D  
Stock Options (Right to Buy) $ 267.87               (12) 08/05/2027 Common Stock 8,325   8,325 D  
Restricted Stock Units (6)               (13)   (13) Common Stock 1,245   1,245 D  
Stock Options (Right to Buy) $ 481.82               (13) 08/06/2028 Common Stock 4,864   4,864 D  
Stock Options (Right to Buy) $ 481.82               (14) 08/06/2028 Common Stock 6,486   6,486 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Kelderman Kim
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413
      Pres. Diagnostics & Genom  

Signatures

 /s/ Brenda S. Furlow as Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.   09/24/2021
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021.
(2) Options to purchase 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
(3) Options to purchase 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
(4) Options to purchase 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022.
(5) Fully exercisable.
(6) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(7) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(8) Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023.
(9) Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(10) Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.
(11) Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
(12) Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
(13) Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(14) Options to purchase 1,621 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,622 shares vest on each of 8/6/2024 and 8/6/2025.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.